FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2953651749> ?p ?o ?g. }

• W2953651749 endingPage "932" @default.
• W2953651749 startingPage "932" @default.
• W2953651749 abstract "Abstract PARP1/2 inhibitors (PARPi) are the first approved targeted DNA damage response (DDR) inhibitors and have been shown to have clinical benefit, particularly in tumors harboring mutations in BRCA1/BRCA2 and other genes of homologous recombination repair (HRR). However, resistance to PARPi monotherapy will impact on both the breadth and depth of response. We showed that HRR-mutant TNBC and ovarian cancer patient-derived tumor xenograft (PDX) models frequently exhibit innate or acquired PARP inhibitor resistance and that this resistance is linked to a proficient or reactivated HRR, indicated by the ability to form RAD51 foci. A key component of PARPi mechanism of action results from trapping PARP onto DNA, which has the potential to generate replication stress. Moreover, recent data demonstrate that PARP1, along with components of the HRR, are associated with the re-start and protection of stalled replication forks. Here, we assessed whether combinations of the PARPi olaparib together with inhibitors of the replication stress response (RSR) could reverse PARPi resistance in our PDX cohort and we analyzed the effects on RSR by immunofluorescence and immunoblotting. Our data demonstrate that 7/27 models exhibit WEE1i (AZD1775) single agent activity measured as tumor regressions (≤ -30% change in tumor volume), all of which were PARPi resistant. Of the PARPi and WEE1i resistant models, 5 responded to combination treatment and demonstrated a significant increase in the RSR markers pRPA32 and pan-γH2AX compared to either single agent treatment alone. For monotherapy ATRi treatment, there were three models showing tumor regression with AZD6738, all harbored ATM mutations, two also responding to WEE1i monotherapy and one responded to olaparib monotherapy. There were an additional two models that responded to the combination of PARPi plus ATRi, and one of these also responded to the WEE1i/PARPi combination. Together, our analysis demonstrates that by targeting the replication stress response we could cause tumor regression in 13/20 PARPi resistant PDX models and in 6 of these cases the response required PARP inhibition, with DDR signalling indicating that the PARPi was impacting on the RSR. Further insights will be presented into which genetic backgrounds and acquired PARPi resistant mechanisms are reversed by targeting either WEE1 or ATR, thus highlighting the potential for how PARPi resistance can be reversed by targeting alternative DDR dependencies. Citation Format: Mark J. O'Connor, Cristina Cruz, Marta Castroviejo-Bermejo, Urszula M. Polanska, Gemma N. Jones, Anderson Wang, Zhongwu Lai, Josep Forment, Krishna Bulusu, Alba Llop-Guevara, Brian Dougherty, Cristina Saura, Rachel Brough, Chris J. Lord, Alejandra Bruna, Carlos Caldas, Stephen Fawell, J Carl Barrett, Susan E. Critchlow, Judith Balmaña, Elaine Cadogan, Violeta Serra. Reversing PARP inhibitor resistance by targeting the replication stress response [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 932." @default.
• W2953651749 created "2019-07-12" @default.
• W2953651749 creator A5012973903 @default.
• W2953651749 creator A5013805263 @default.
• W2953651749 creator A5018587370 @default.
• W2953651749 creator A5022677387 @default.
• W2953651749 creator A5031229355 @default.
• W2953651749 creator A5036350682 @default.
• W2953651749 creator A5037908617 @default.
• W2953651749 creator A5042431454 @default.
• W2953651749 creator A5053924692 @default.
• W2953651749 creator A5057710096 @default.
• W2953651749 creator A5058717267 @default.
• W2953651749 creator A5067794408 @default.
• W2953651749 creator A5071581968 @default.
• W2953651749 creator A5076784474 @default.
• W2953651749 creator A5078491431 @default.
• W2953651749 creator A5082195410 @default.
• W2953651749 creator A5083333226 @default.
• W2953651749 creator A5083605021 @default.
• W2953651749 creator A5087646089 @default.
• W2953651749 creator A5089060804 @default.
• W2953651749 creator A5091683932 @default.
• W2953651749 creator A5023443663 @default.
• W2953651749 date "2019-07-01" @default.
• W2953651749 modified "2023-09-27" @default.
• W2953651749 title "Abstract 932: Reversing PARP inhibitor resistance by targeting the replication stress response" @default.
• W2953651749 doi "https://doi.org/10.1158/1538-7445.am2019-932" @default.
• W2953651749 hasPublicationYear "2019" @default.
• W2953651749 type Work @default.
• W2953651749 sameAs 2953651749 @default.
• W2953651749 citedByCount "0" @default.
• W2953651749 crossrefType "journal-article" @default.
• W2953651749 hasAuthorship W2953651749A5012973903 @default.
• W2953651749 hasAuthorship W2953651749A5013805263 @default.
• W2953651749 hasAuthorship W2953651749A5018587370 @default.
• W2953651749 hasAuthorship W2953651749A5022677387 @default.
• W2953651749 hasAuthorship W2953651749A5023443663 @default.
• W2953651749 hasAuthorship W2953651749A5031229355 @default.
• W2953651749 hasAuthorship W2953651749A5036350682 @default.
• W2953651749 hasAuthorship W2953651749A5037908617 @default.
• W2953651749 hasAuthorship W2953651749A5042431454 @default.
• W2953651749 hasAuthorship W2953651749A5053924692 @default.
• W2953651749 hasAuthorship W2953651749A5057710096 @default.
• W2953651749 hasAuthorship W2953651749A5058717267 @default.
• W2953651749 hasAuthorship W2953651749A5067794408 @default.
• W2953651749 hasAuthorship W2953651749A5071581968 @default.
• W2953651749 hasAuthorship W2953651749A5076784474 @default.
• W2953651749 hasAuthorship W2953651749A5078491431 @default.
• W2953651749 hasAuthorship W2953651749A5082195410 @default.
• W2953651749 hasAuthorship W2953651749A5083333226 @default.
• W2953651749 hasAuthorship W2953651749A5083605021 @default.
• W2953651749 hasAuthorship W2953651749A5087646089 @default.
• W2953651749 hasAuthorship W2953651749A5089060804 @default.
• W2953651749 hasAuthorship W2953651749A5091683932 @default.
• W2953651749 hasConcept C102744134 @default.
• W2953651749 hasConcept C104317684 @default.
• W2953651749 hasConcept C121608353 @default.
• W2953651749 hasConcept C134935766 @default.
• W2953651749 hasConcept C143425029 @default.
• W2953651749 hasConcept C178169997 @default.
• W2953651749 hasConcept C182979987 @default.
• W2953651749 hasConcept C2778480876 @default.
• W2953651749 hasConcept C2778502085 @default.
• W2953651749 hasConcept C2779012473 @default.
• W2953651749 hasConcept C2779138821 @default.
• W2953651749 hasConcept C2779962180 @default.
• W2953651749 hasConcept C501734568 @default.
• W2953651749 hasConcept C502942594 @default.
• W2953651749 hasConcept C54355233 @default.
• W2953651749 hasConcept C552990157 @default.
• W2953651749 hasConcept C71924100 @default.
• W2953651749 hasConcept C82381507 @default.
• W2953651749 hasConcept C86803240 @default.
• W2953651749 hasConceptScore W2953651749C102744134 @default.
• W2953651749 hasConceptScore W2953651749C104317684 @default.
• W2953651749 hasConceptScore W2953651749C121608353 @default.
• W2953651749 hasConceptScore W2953651749C134935766 @default.
• W2953651749 hasConceptScore W2953651749C143425029 @default.
• W2953651749 hasConceptScore W2953651749C178169997 @default.
• W2953651749 hasConceptScore W2953651749C182979987 @default.
• W2953651749 hasConceptScore W2953651749C2778480876 @default.
• W2953651749 hasConceptScore W2953651749C2778502085 @default.
• W2953651749 hasConceptScore W2953651749C2779012473 @default.
• W2953651749 hasConceptScore W2953651749C2779138821 @default.
• W2953651749 hasConceptScore W2953651749C2779962180 @default.
• W2953651749 hasConceptScore W2953651749C501734568 @default.
• W2953651749 hasConceptScore W2953651749C502942594 @default.
• W2953651749 hasConceptScore W2953651749C54355233 @default.
• W2953651749 hasConceptScore W2953651749C552990157 @default.
• W2953651749 hasConceptScore W2953651749C71924100 @default.
• W2953651749 hasConceptScore W2953651749C82381507 @default.
• W2953651749 hasConceptScore W2953651749C86803240 @default.
• W2953651749 hasIssue "13_Supplement" @default.
• W2953651749 hasLocation W29536517491 @default.
• W2953651749 hasOpenAccess W2953651749 @default.
• W2953651749 hasPrimaryLocation W29536517491 @default.
• W2953651749 hasRelatedWork W2056920544 @default.

• next